Logo

Kodiak Reports Results of KSI-301 in P-IIb/III Study for the Treatment of Age-Related Macular Degeneration

Share this
Kodiak Reports Results of KSI-301 in P-IIb/III Study for the Treatment of Age-Related Macular Degeneration

Kodiak Reports Results of KSI-301 in P-IIb/III Study for the Treatment of Age-Related Macular Degeneration

Shots:

  • The P-IIb/III trial evaluates KSI-301 vs aflibercept (q8w) in 559 treatment-naïve patients with neovascular AMD
  • The study did not meet the 1EPs of non-inferior visual acuity gains in patients dosed on extended regimens, strong durability, was safe & well tolerated with no new safety signals. In a pre-specified secondary analysis, 59% of patients achieved 5mos. dosing @1yr. with visual acuity gains & anatomic improvements over aflibercept
  • KSI-301 is being studied at 150+ study sites in 10+ countries. The results from the P-III (GLEAM) and (GLIMMER) for DME along with (DAYLIGHT) study for wet AMD are expected in early 2023

 Ref: PR Newswire | Image: Stock Light

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions